The agreement with Wugen is likely to have a positive short-term impact on MaxCyte's stock price as it not only expands the use of MaxCyte's technology but also ensures a steady stream of revenue through annual license fees and program-related payments. This deal demonstrates the value and demand for MaxCyte's Flow Electroporation and ExPERT platform in the market, which could be seen as a positive indicator by investors.